Obstructive Sleep Apnoea (OSA)

1. Clinical Overview

Summary

Obstructive Sleep Apnoea (OSA) is a chronic sleep disorder characterized by repetitive collapse of the upper airway (pharynx) during sleep, leading to cessation of airflow (apnea), intermittent hypoxia, and sleep fragmentation. It is the leading cause of Excessive Daytime Sleepiness (EDS) and a major independent risk factor for cardiovascular morbidity, including resistant hypertension, atrial fibrillation, and stroke.

The core pathology is a "Starling Resistor" failure: the negative pressure generated by the diaphragm overcomes the structural stability of the pharyngeal dilator muscles, causing the airway to suck closed like a wet straw. This cycle repeats hundreds of times a night, triggering sympathetic surges (fight-or-flight) that wreck metabolic and vascular health.

Diagnosis is confirmed by Polysomnography (PSG) or Home Sleep Apnea Testing (HSAT), measuring the Apnea-Hypopnea Index (AHI). An AHI > 5/hour confirms diagnosis, but treatment is typically reserved for symptomatic moderate-severe disease (AHI > 15). Management typically follows a staircase: Lifestyle (Weight loss/Positional therapy) -> CPAP (Gold Standard) -> Mandibular Advancement Devices (MAD). Crucially, physicians have a statutory duty to advise patients regarding Driving Safety. Uncontrolled OSA with sleepiness is a bar to driving (DVLA/DMV).

Key Facts

• Prevalence: 4% of men, 2% of women (symptomatic). Up to 24% of men have asymptomatic AHI > 5.
• Strongest Risk Factor: Obesity (Neck Circumference > 43cm in men).
• Key Symptom: Witnessed apneas ("He stops breathing and then snorts").
• Gold Standard Treatment: CPAP (Continuous Positive Airway Pressure).
• Cardiovascular Link: 50% of patients with Atrial Fibrillation have OSA.

Clinical Pearls

Clinical Pearl: The "Reverse Dipper": In normal people, BP drops at night. In OSA, the sympathetic surges cause BP to rise or stay high at night ("Non-dipping"). Suspect OSA in anyone with nocturnal hypertension or resistant hypertension.

Clinical Pearl: The "Thick Neck" Rule: Neck circumference is a better predictor of OSA than BMI. > 43cm (17 inches) in men or > 40.5cm (16 inches) in women is high risk.

Clinical Pearl: "It's not just fat men": Post-menopausal women and thin patients with retrognathia (receding chin) are frequently missed. In Asians, craniofacial structure is a bigger driver than BMI.

Clinical Pearl: The "Morning Headache": A dull, frontal headache on waking that clears up after an hour often signals CO2 retention (Hypercapnia) or poor sleep quality.

Clinical Pearl: The "Dry Mouth": Waking up with a dry mouth often indicates mouth-breathing due to nasal obstruction or OSA gasping.

Why This Matters Clinically

Public Safety: Untreated OSA drivers are 6x more likely to have a road traffic accident. Peri-operative Risk: OSA patients are highly sensitive to opioids and sedatives, risking respiratory arrest on the ward. Stroke Prevention: Treating OSA reduces recurrence of Atrial Fibrillation post-ablation.

---

2. Epidemiology

Prevalence & Incidence

Obstructive Sleep Apnoea represents a global health epidemic with a staggering burden of disease that continues to rise in parallel with the obesity pandemic. Recent systematic analyses reveal the true scale of this condition.

Global Prevalence Data:

• Global Burden: Approximately 936 million adults aged 30-69 have mild-to-severe OSA (AHI ≥5), with 425 million suffering moderate-to-severe disease (AHI ≥15) worldwide. [23]
• Regional Variation: Highest prevalence in China (male 23.6%, female 3.9%), lowest in Nigeria (male 8.9%, female 3.1%). High-income nations show higher prevalence, likely due to obesity and better diagnostic access. [24]
• Population Studies: In the Wisconsin Sleep Cohort, 14% of men and 5% of women aged 30-70 had moderate-to-severe OSA. Modern estimates suggest up to 49% of middle-aged men have clinically significant OSA (AHI ≥10). [25,26]
• Underdiagnosis Crisis: An estimated 80-90% of moderate-severe OSA cases remain undiagnosed globally, representing a massive public health gap. [27]

Demographic Distribution:

• Male:Female Ratio: 2-3:1 in pre-menopausal women. This narrows to 1:1 post-menopause due to loss of progesterone (a respiratory stimulant) and upper airway muscle tone. [8]
• Age: Prevalence rises steeply with age. OSA affects 20% of adults greater than 60 years, increasing to 30-50% in those greater than 65 years, related to loss of pharyngeal muscle tone and increased fat deposition. [28]
• Ethnicity: Asians develop OSA at lower BMI thresholds due to craniofacial structure (shorter mandible, narrower airway). African-Americans have 2x risk compared to Caucasians. [29]

Temporal Trends:

• OSA prevalence has increased by 14-55% over the past two decades, driven primarily by the obesity epidemic. In the United States alone, the prevalence of moderate-to-severe OSA rose from 10% (1988-1994) to 17% (2007-2010). [30]

Risk Factors Classification

OSA is a multifactorial condition with anatomical, physiological, lifestyle, and medical contributors. Understanding risk factors enables targeted screening and prevention strategies.

---

3. Pathophysiology

The Starling Resistor Model

The upper airway (pharynx) is a collapsible tube lacking rigid structural support (unlike the trachea, which has cartilage). Its patency depends on a dynamic balance of opposing forces.

1. Patency depends on the balance between:
   • Dilating Force: Pharyngeal dilator muscle tone (Genioglossus, Tensor Palatini, Levator Palatini).
   • Collapsing Force: Negative intraluminal pressure (suction from diaphragm during inspiration) + Extraluminal tissue pressure (fat, edema, anatomical crowding).
2. During Wakefulness: Muscle tone is maintained by cortical input and pharyngeal mechanoreceptor feedback. The airway stays open.
3. During Sleep: Muscle tone naturally relaxes. Cortical drive is lost. Mechanoreceptor sensitivity decreases.
4. In OSA: The collapsing forces (obesity, anatomy) exceed the reduced muscle dilating force. The airway collapses at the level of the velopharynx (soft palate) and/or oropharynx (tongue base). [46]

Critical Closing Pressure (Pcrit):

• Pcrit is the nasal pressure at which the airway collapses during sleep. In normal individuals, Pcrit is negative (around -5 cmH₂O), meaning the airway is stable even with negative inspiratory pressure.
• In OSA patients, Pcrit is positive (+2 to +5 cmH₂O), meaning the airway collapses unless positive pressure is applied externally (CPAP). [47]

Stepwise Pathophysiology: The Loop of Doom

The pathophysiology of OSA is a vicious, self-perpetuating cycle that occurs hundreds of times per night, with devastating systemic consequences.

Step 1: Sleep Onset & Muscle Relaxation

• Patient falls asleep. Pharyngeal dilator muscles (Genioglossus, palatine muscles) relax.
• Airway narrows (Hypopnea) or closes completely (Apnea).
• Collapse typically occurs at the level of the velopharynx (retropalatal) and oropharynx (retroglossal).

Step 2: Cessation of Airflow

• Despite ongoing respiratory effort (chest and abdomen move paradoxically), no air enters the lungs.
• Alveolar Hypoxia develops. Oxyhemoglobin saturation (SpO₂) drops, often to 70-80% in severe cases.
• Hypercapnia (CO₂ retention) occurs due to lack of gas exchange. PaCO₂ rises.

Step 3: Chemoreceptor Trigger

• Peripheral chemoreceptors (carotid bodies) detect Hypoxia and Hypercapnia.
• Central chemoreceptors (medulla) sense rising CO₂ and falling pH.
• Signals are sent to Brainstem arousal centers (Reticular Activating System).

Step 4: Micro-Arousal (Cortical Awakening)

• The brain "wakes up" briefly (3-15 seconds) – rarely consciously remembered by the patient.
• This is not full awakening; it is a transient shift from deeper sleep (N3/REM) to lighter sleep (N1/N2) or brief wakefulness.
• Muscle tone is restored to pharyngeal dilators.

Step 5: Restoration of Airflow

• Airway pops open, often with a loud Snort, Gasp, or Choke (witnessed by bed partner).
• Hyperventilation occurs to "wash out" CO₂ and restore oxygenation.
• SpO₂ rapidly recovers (often within 10-20 seconds).

Step 6: Hemodynamic Surge (The "Cardiovascular Hit")

• The arousal triggers a massive Sympathetic Nervous System Discharge.
• Catecholamines (Adrenaline, Noradrenaline) are released.
• Heart rate spikes (tachycardia). Blood pressure spikes (often 20-30 mmHg acutely).
• Cortisol is released (stress response).
• Result: Repetitive nocturnal hypertension, vascular shearing stress, endothelial dysfunction, and oxidative stress. [48]

Step 7: Return to Sleep & Cycle Repetition

• Patient falls back asleep. Muscle tone relaxes again. Airway collapses again.
• The cycle repeats 5-100 times per hour, every night, for years, causing cumulative damage.

Molecular Mechanisms: Intermittent Hypoxia & Inflammation

The repetitive hypoxia-reoxygenation cycles are not benign. They trigger a cascade of molecular pathways that drive systemic disease.

1. Oxidative Stress:

• Hypoxia-reoxygenation mimics "ischemia-reperfusion injury."
• Reactive Oxygen Species (ROS) generation overwhelms antioxidant defenses.
• Lipid peroxidation, DNA damage, and protein oxidation occur. [49]

2. Systemic Inflammation:

• Pro-inflammatory cytokines (IL-6, TNF-α, CRP) are elevated.
• NF-κB pathway activation drives chronic low-grade inflammation.
• This promotes atherosclerosis, insulin resistance, and neurodegeneration. [50]

3. Endothelial Dysfunction:

• Nitric oxide (NO) bioavailability is reduced (impaired vasodilation).
• Endothelin-1 (vasoconstrictor) is upregulated.
• Result: Hypertension, increased arterial stiffness, and accelerated atherosclerosis. [51]

4. Sympathetic Overactivity:

• Chronic elevation of sympathetic tone (even during wakefulness).
• Contributes to hypertension, arrhythmias (Atrial Fibrillation), and sudden cardiac death. [52]

5. Metabolic Dysregulation:

• Intermittent hypoxia activates Hypoxia-Inducible Factor-1α (HIF-1α).
• HIF-1α promotes glycolysis, impairs insulin signaling, and increases hepatic glucose production.
• Result: Insulin resistance, hyperglycemia, and increased risk of Type 2 Diabetes. [40]

6. Coagulation Activation:

• Elevated levels of fibrinogen, Factor VII, and plasminogen activator inhibitor-1 (PAI-1).
• Increased platelet activation and aggregation.
• Result: Prothrombotic state, increasing risk of Stroke and Myocardial Infarction. [53]

Unique OSA Phenomena: Why This Matters Clinically

1. Negative Intrathoracic Pressure Swings:

• During obstructed inspiration, huge negative intrathoracic pressures are generated (up to -80 cmH₂O, vs. -5 cmH₂O in normal breathing).
• This "sucks" blood into the right heart (increased venous return), stretching the atria and releasing Atrial Natriuretic Peptide (ANP).
• Result: Nocturia (one of the cardinal symptoms of OSA). [54]

2. Non-Dipping Blood Pressure:

• In healthy individuals, nocturnal BP drops by 10-20% ("dipping").
• In OSA, repetitive sympathetic surges cause BP to rise or stay elevated at night ("non-dipping" or "reverse dipping").
• Non-dipping is a strong predictor of cardiovascular events. [55]

3. REM-Related Worsening:

• OSA is often worse during REM sleep because muscle atonia (paralysis) is maximal during REM, causing further loss of pharyngeal tone.
• "REM-predominant OSA" may be particularly linked to hypertension. [56]

Site of Obstruction

Obstruction in OSA is not uniform. The pharynx can collapse at multiple levels:

Most OSA patients have multi-level obstruction (both retropalatal and retroglossal). This has implications for surgical treatment (single-level surgery often fails). [57]

---

4. Clinical Presentation

Symptom Profiling

Nocturnal Symptoms (Bed partner usually reports):

• Loud, habitual snoring (often pauses -> silence -> snort).
• Witnessed apneas ("I thought he died").
• Choking/Gasping.
• Restless sleep (thrashing).
• Nocturia (ANP release due to negative thoracic pressure stretching the heart).

Daytime Symptoms:

• Excessive Daytime Sleepiness (EDS): Falling asleep at work, TV, or driving.
• Unrefreshing sleep ("Woke up tired").
• Morning headache (Dry mouth).
• Cognitive dysfunction (Brain fog, memory loss).
• Irritability/Depression.
• Libido loss / Erectile dysfunction.

Screening Tool: The STOP-BANG Questionnaire

Score > 3 = High sensitivity for OSA. Score > 5 = High risk of Moderate/Severe OSA.

Red Flags

[!CAUTION] OSA Red Flags - Urgent Action Required:

• Professional Driver: Truck/Bus/Train driver with sleepiness. Must cease driving immediately.
• Drowsy Driving: History of near-misses or falling asleep at the wheel.
• Respiratory Failure: SpO2 less than 92% awake, leg edema (Cor Pulmonale).
• Pregnancy: High risk of Pre-eclampsia/Fetal growth restriction.
• Pre-operative: High risk of airway collapse with anaesthesia.

---

5. Clinical Examination

Structured Approach

1. General

• BMI Calculation.
• Neck Circumference Measurement (at cricothyroid membrane).
• Blood Pressure (often elevated).

2. Face & Neck

• Retrognathia: Receding chin? (Bird-like face).
• Nasal patency: Deviated septum? Polyps?
• Thyroid: Goiter?

3. Oropharynx (The Mallampati Score) Ask patient to open mouth and protrude tongue (No "Ahhh").

• Class I: Full visualization of soft palate, uvula, and pillars.
• Class II: Uvula visible but pillars hidden.
• Class III: Only soft palate base visible (Uvula hidden).
• Class IV: Only Hard Palate visible. (High Risk).
• Tonsils: Grade 1-4 (Kissing tonsils = Grade 4).

---

6. Investigations

The Epworth Sleepiness Scale (ESS)

Used to quantify EDS. Score > 10 is abnormal. Score > 16 is severe.

Polysomnography (The Gold Standard)

Can be Level 1 (In-lab technician attended) or Level 3 (Home Sleep Apnea Test - HSAT).

What is measured?

1. EEG/EOG/EMG: To stage sleep (REM vs NREM). (Only in Level 1).
2. Airflow: Nasal cannula pressure.
3. Effort: Chest and Abdominal bands (Paradoxical movement = Obstructive).
4. Oximetry: SpO2 and Heart Rate.
5. Position: Supine vs Lateral.

Differential Diagnosis: The "Sleepy Three"

Interpretation Criteria (AASM 2012)

Severity Grading (Adults)

Other Tests

• TFTs/IGF-1: Rule out Hypothyroidism/Acromegaly.
• ABG: If SpO2 less than 92% awake (Rule out Obesity Hypoventilation Syndrome).

---

7. Management

Management Algorithm

AI-Generated Management Algorithm Image Required:

Image

Algorithm Content:

1. Suspect: STOP-BANG > 3 or Snoring + Tired.
2. Diagnose: HSAT or PSG. Define AHI.
3. Mild (AHI 5-15): Conservative (Weight/Mandibular Device).
4. Moderate/Severe (AHI > 15): CPAP is First Line.
5. Refractory/Intolerant: Surgery or Hypoglossal Nerve Stimulation.

1. Conservative & Lifestyle

• Weight Loss: Crucial. 10% weight loss can reduce AHI by 26%.
  • GLP-1 Agonists (Semaglutide): Emerging evidence shows significant AHI reduction driven by weight loss.
  • Bariatric Surgery: Curative in many morbidly obese patients.
• Positional Therapy: "Tennis ball technique" or vibrators to prevent supine sleep (if positional OSA).
• Alcohol/Sedative Avoidance: Especially before bed.

2. Medical Management (Pharmacotherapy)

• Residual Sleepiness: If patient is compliant with CPAP (> 4h) but still sleepy:
  • Modafinil 200 mg OD (wakefulness promoter).
  • Solriamfetol.
• Weight Loss:
  • Semaglutide 2.4 mg SC Weekly (GLP-1 agonist).

3. Continuous Positive Airway Pressure (CPAP)

Mechanism: A pneumatic splint. It blows pressurized air to keep the airway open against the collapsing forces. Efficacy: 100% effective if worn. The issue is adherence. Compliance Definition: Usage > 4 hours/night for > 70% of nights.

Interface Options Table:

CPAP Prescription Guide (The "Standard" Order)

For a GP or Junior Doctor prescribing/managing CPAP:

• Mode: Auto-CPAP (APAP).
• Pressure Range: 4 - 20 cmH2O (Machine creates a Pneumatic Splint).
• Ramp Time: 20 minutes (Starts at 4, slowly builds up to help patient fall asleep).
• EPR (Expiratory Pressure Relief): Level 2 or 3 (Drops pressure when breathing out to reduce bloating).
• Humidification: Necessary for adherence. Set to Level 3-4.

CPAP Survival Guide: Troubleshooting Common Issues

Contraindications to CPAP

[!WARNING] Use CPAP with Caution (or Avoid) in:

• Bullous Lung Disease: Risk of Pneumothorax.
• CSF Leak: Risk of Pneumocephalus (Air forced into brain).
• Recent Facial Surgery/Trauma: Mask pressure/Air dissection.
• Epistaxis: Severe recurrent nosebleeds.

3. Mandibular Advancement Devices (MAD)

• Mechanism: A custom dental splint that pulls the lower jaw forward, pulling the tongue off the posterior pharyngeal wall.
• Indication: Mild-Moderate OSA, or CPAP intolerant.
• Pros: Silent, portable, no power needed.
• Cons: TMJ pain, tooth movement, drooling.

4. Surgery (ENT)

• Tonsillectomy: Curative in children. Often adjunct in adults.
• UPPP (Uvulopalatopharyngoplasty): Removal of uvula and soft palate trim. Painful. Variable success (40-50%).
• Hypoglossal Nerve Stimulation (Inspire): Implanted pacemaker for the tongue. Stimulates protrusion during inspiration. For CPAP-failed moderate/severe patients.

---

8. Complications

OSA is not merely a sleep disorder; it is a systemic disease with far-reaching consequences affecting nearly every organ system. The chronic intermittent hypoxia, sympathetic overactivity, and sleep fragmentation drive a cascade of pathology.

1. Cardiovascular Complications

Hypertension (Most Common):

• Prevalence: 50-60% of OSA patients have hypertension. Conversely, 30-40% of hypertensives have OSA. [58]
• Resistant Hypertension: OSA is present in 80-90% of patients with resistant hypertension (BP uncontrolled despite ≥3 antihypertensives). [59]
• Mechanism: Nocturnal sympathetic surges, endothelial dysfunction, RAAS activation, non-dipping BP pattern.
• Evidence: CPAP therapy reduces BP by 2-5 mmHg (significant at population level). [60]

Atrial Fibrillation (AF):

• Prevalence: OSA is present in 50-80% of patients with AF. [61]
• Mechanism: Atrial stretch (negative intrathoracic pressure), atrial fibrosis (chronic hypoxia/inflammation), autonomic dysregulation.
• Impact: Untreated OSA increases AF recurrence post-cardioversion and post-ablation by 50-80%. [62]
• Evidence: CPAP reduces AF recurrence after catheter ablation (RR 0.58). [63]

Heart Failure:

• Prevalence: OSA in 40-50% of heart failure patients (both HFrEF and HFpEF). [64]
• Mechanism: Increased afterload (hypertension), myocardial ischemia, arrhythmias, diastolic dysfunction.
• Bidirectional: Heart failure worsens OSA (fluid shifts to neck when supine). OSA worsens heart failure (increased sympathetic tone, hypertension).

Coronary Artery Disease (CAD) & Myocardial Infarction:

• Risk: Severe OSA (AHI greater than 30) increases MI risk by 2-3 fold. [11]
• Mechanism: Accelerated atherosclerosis (endothelial dysfunction, inflammation, oxidative stress), nocturnal myocardial ischemia, plaque instability.
• Nocturnal MI: Patients with OSA have a higher proportion of MIs occurring at night (vs. morning in non-OSA). [65]

Stroke:

• Risk: OSA increases stroke risk by 2-4 fold (independent of other risk factors). [12,13]
• Mechanism: Hypertension, AF, hypercoagulability, cerebral hypoxia, impaired cerebral autoregulation.
• Post-Stroke OSA: 50-70% of stroke patients have OSA. OSA worsens stroke recovery and increases recurrence risk. [43]

Sudden Cardiac Death:

• OSA patients have increased risk of sudden cardiac death during sleeping hours (midnight to 6 AM), unlike the general population (peak 6 AM to noon). [66]
• Mechanism: Severe hypoxemia, arrhythmias, autonomic instability.

2. Metabolic Complications

Type 2 Diabetes Mellitus:

• Bidirectional Relationship: OSA increases diabetes risk. Diabetes increases OSA risk (neuropathy, obesity).
• Prevalence: OSA in 86% of obese Type 2 diabetics. [40]
• Mechanism: Intermittent hypoxia → HIF-1α activation → Insulin resistance, impaired glucose tolerance, increased hepatic gluconeogenesis.
• Evidence: Severe OSA increases incident diabetes risk by 30-50%. CPAP improves insulin sensitivity and glycemic control. [67]

Metabolic Syndrome:

• OSA is strongly associated with metabolic syndrome (central obesity, hypertension, dyslipidemia, insulin resistance).
• Prevalence: 60-80% of OSA patients meet criteria for metabolic syndrome. [68]

Dyslipidemia:

• OSA is associated with elevated triglycerides, LDL cholesterol, and reduced HDL cholesterol.
• Mechanism: Upregulation of lipogenic enzymes, impaired lipoprotein clearance. [69]

Non-Alcoholic Fatty Liver Disease (NAFLD):

• OSA independently predicts NAFLD and non-alcoholic steatohepatitis (NASH).
• Mechanism: Intermittent hypoxia → hepatic oxidative stress, lipid peroxidation, fibrosis. [70]

3. Neurocognitive Complications

Cognitive Impairment:

• OSA causes deficits in attention, executive function, memory, and psychomotor speed.
• Mechanism: Sleep fragmentation, chronic intermittent hypoxia, reduced slow-wave sleep (critical for memory consolidation). [71]

Dementia:

• OSA accelerates cognitive decline and increases risk of Alzheimer's Disease and Vascular Dementia.
• Mechanism: Chronic hypoxia, vascular damage, impaired clearance of amyloid-β (sleep disruption impairs glymphatic clearance). [72]
• Evidence: OSA may accelerate dementia onset by 10 years if untreated. CPAP may slow cognitive decline. [73]

Depression & Anxiety:

• Prevalence: Depression in 40-50% of OSA patients. Anxiety in 30-40%. [74]
• Mechanism: Sleep deprivation, chronic hypoxia, disrupted neurotransmitter regulation (serotonin, dopamine).
• Bidirectional: Depression worsens OSA symptoms. OSA treatment improves mood.

Motor Vehicle Accidents:

• OSA patients have 2-7 times higher risk of road traffic accidents due to excessive daytime sleepiness and impaired vigilance. [75]
• Commercial drivers (HGV, bus) have particularly high risk.

4. Pregnancy Complications

OSA in pregnancy is associated with significant maternal and fetal risks. Pregnancy-related weight gain, fluid retention, and upper airway edema increase OSA prevalence.

Maternal Complications:

• Preeclampsia: OSA increases risk 2-2.5 fold. [76,77,78]
  • Mechanism: Shared pathways (endothelial dysfunction, oxidative stress, hypertension, inflammation).
• Eclampsia: 3-4 fold increased risk. [76]
• Gestational Diabetes: 1.5 fold increased risk. [79]
• Postpartum Hemorrhage: 1.4 fold increased risk. [76]
• Cesarean Section: 1.6 fold increased risk (often for fetal distress or maternal complications). [80]

Fetal/Neonatal Complications:

• Intrauterine Growth Restriction (IUGR): Chronic maternal hypoxemia impairs placental perfusion. [81]
• Preterm Birth: 1.9-2.9 fold increased risk. [77,80]
• Low Birth Weight: Associated with maternal OSA severity.
• Stillbirth: Rare but increased risk in severe untreated OSA.

Management: CPAP is safe in pregnancy and improves maternal BP and fetal outcomes. [82]

5. Perioperative Complications

OSA patients are at high risk during and after surgery, particularly with general anesthesia and opioid analgesia.

Complications:

• Difficult intubation: Due to anatomical factors (retrognathia, large tongue, narrow airway).
• Postoperative respiratory failure: Opioids and sedatives suppress respiratory drive and upper airway tone, precipitating apneas.
• Hypoxemia: Increased risk of desaturation, aspiration, and respiratory arrest on the ward.
• Cardiovascular events: MI, arrhythmias, stroke (due to hypoxemia, sympathetic surges).

STOP-BANG in Anesthesia:

• STOP-BANG score ≥5 predicts high perioperative risk. [83]
• Patients should be monitored in high-dependency units. Avoid opioids where possible. Use regional/neuraxial anesthesia.
• Bring CPAP machine to hospital for postoperative use.

6. Other Complications

Pulmonary Hypertension & Cor Pulmonale:

• Chronic nocturnal hypoxemia → pulmonary vasoconstriction → pulmonary hypertension → right heart failure.
• More common if coexisting COPD ("Overlap Syndrome") or Obesity Hypoventilation Syndrome.

Chronic Kidney Disease:

• OSA independently predicts incident CKD and CKD progression.
• Mechanism: Hypertension, endothelial dysfunction, oxidative stress, RAAS activation. [84]

Glaucoma:

• OSA increases risk of normal-tension glaucoma and open-angle glaucoma.
• Mechanism: Nocturnal hypoxia → optic nerve ischemia. [85]

Gastroesophageal Reflux Disease (GERD):

• Large negative intrathoracic pressure swings promote reflux.
• GERD worsens OSA (acid irritation → pharyngeal edema). Bidirectional relationship. [86]

Sexual Dysfunction:

• Erectile dysfunction in 40-70% of men with OSA.
• Mechanism: Endothelial dysfunction, low testosterone, fatigue, depression. [87]
• CPAP improves erectile function in 30-50% of cases.

---

9. Prognosis & Outcomes

• With CPAP: Normalizes mortality risk to that of general population. Symptoms (EDS) usually resolve within 2 weeks. Hypertension control improves.
• Without Treatment: Severe OSA carries significant mortality risk (Fatal MI/Stroke) and accident risk.

---

10. Special Populations

OSA in Pregnancy

Pregnancy represents a unique physiological challenge that increases OSA risk and severity, with important implications for both maternal and fetal health.

Why Does Pregnancy Increase OSA Risk?

• Weight Gain: Average 11-16 kg gain → increased parapharyngeal fat.
• Fluid Retention: Edema of upper airway tissues (especially in 3rd trimester).
• Hormonal Changes: Progesterone is a respiratory stimulant, but this is overwhelmed by other factors. Estrogen causes nasal congestion.
• Decreased FRC: Gravid uterus elevates diaphragm, reducing functional residual capacity and oxygen reserve.

Prevalence:

• OSA prevalence rises from 10% (1st trimester) to 27% (3rd trimester). [42]
• Higher risk in obese, older (greater than 35 yrs), and multiparous women.

Screening:

• STOP-BANG can be used, but modified thresholds may be needed (pregnancy increases false positives).
• Consider sleep study if: Loud snoring + witnessed apneas + chronic hypertension or gestational hypertension.

Management:

• CPAP is safe and recommended for moderate-severe OSA. No evidence of fetal harm. Improves maternal BP and reduces preeclampsia risk. [82]
• Avoid sedatives and hypnotics (worsen OSA and risk fetal depression).
• Lateral sleeping position (left lateral) reduces supine OSA and improves uteroplacental perfusion.
• Postpartum: OSA often improves after delivery, but may not fully resolve, especially if pre-pregnancy obesity persists.

OSA in the Elderly (greater than 65 Years)

OSA is highly prevalent in older adults (30-50%), but is often underdiagnosed due to atypical presentation and overlap with other conditions.

Unique Features in Elderly OSA:

• Atypical Symptoms: Less likely to report snoring or witnessed apneas. More likely to present with nocturia, confusion, falls, or "just tired."
• Lower ESS Scores: Elderly may not report sleepiness (reduced activity levels, acceptance of fatigue as "normal aging").
• Comorbidity Burden: High prevalence of hypertension, AF, heart failure, stroke, dementia (both cause and consequence of OSA).
• Central Sleep Apnea: More common in elderly, especially with heart failure or stroke.

Management Considerations:

• CPAP Adherence: Elderly may have better adherence (stable routines, understanding of health risks) or worse (cognitive impairment, manual dexterity issues, claustrophobia).
• Interface Selection: Full-face masks better tolerated if edentulous or mouth-breathing. Nasal pillows if claustrophobic.
• Cognitive Benefits: CPAP may slow cognitive decline and reduce dementia risk. [73]
• Fall Risk: Treat nocturia (related to OSA) to reduce nighttime falls.

Evidence:

• Treating OSA in elderly improves quality of life, BP control, and cognitive function. Mortality benefit less clear (competing causes of death). [88]

OSA in Women

OSA is significantly underdiagnosed in women due to sex-specific differences in presentation, symptoms, and clinical awareness.

Why Underdiagnosed?

• Atypical Symptoms: Women less likely to snore loudly or have witnessed apneas. More likely to report insomnia, fatigue, morning headaches, depression, and anxiety.
• Clinical Bias: OSA is perceived as a "male disease." Women less likely to be referred for sleep studies.
• Different Anatomy: Women have smaller, less collapsible airways (protective pre-menopause). Less neck fat deposition.

Risk Factors Unique to Women:

• Menopause: Dramatic increase in OSA prevalence post-menopause (approaches male prevalence). [8]
• Polycystic Ovary Syndrome (PCOS): OSA in 35-70% due to hyperandrogenism, obesity, insulin resistance. [41]
• Pregnancy: See above.

Clinical Presentation:

• Pre-menopause: OSA often milder. More insomnia, fatigue, depression, headaches. Less snoring/gasping.
• Post-menopause: Presentation becomes more similar to men (snoring, witnessed apneas, sleepiness).

Management:

• Same principles as men (CPAP first-line for moderate-severe).
• Address comorbid insomnia (CBT-I, sleep hygiene) – more common in women.
• Screen for depression/anxiety (may improve with CPAP, but may need separate treatment).

Evidence:

• CPAP improves quality of life, mood, and cardiovascular outcomes in women, but adherence may be lower due to interface discomfort and cosmetic concerns. [89]

OSA in Patients with Down Syndrome

OSA affects 50-100% of individuals with Down Syndrome (Trisomy 21), across all ages (infants to adults). [90]

Why So Common?

• Anatomical: Midface hypoplasia, narrow nasopharynx, macroglossia, adenotonsillar hypertrophy, obesity.
• Physiological: Hypotonia (reduced pharyngeal muscle tone), obesity (common in adults).

Diagnosis:

• High Index of Suspicion: Assume OSA is present until proven otherwise.
• Polysomnography recommended for all children and adults with Down Syndrome.

Management:

• Children: Adenotonsillectomy is first-line (but only curative in 30-50% due to residual anatomical factors). CPAP if surgery fails or not candidate.
• Adults: CPAP first-line. Weight loss (if obese). Consider MAD (if cognitively able to use).
• Challenges: CPAP adherence can be difficult (intellectual disability, sensory sensitivities). Family/caregiver support critical.

OSA in Patients with Neuromuscular Disease

OSA and Central Sleep Apnea are common in neuromuscular diseases (Duchenne Muscular Dystrophy, Myasthenia Gravis, ALS, Post-Polio Syndrome).

Mechanisms:

• Bulbar weakness → pharyngeal collapse, impaired airway protection.
• Respiratory muscle weakness → hypoventilation (overlap with central apneas).
• Kyphoscoliosis → restrictive lung disease.

Management:

• BiPAP (Bilevel PAP) often needed (provides both inspiratory and expiratory support). CPAP alone may be insufficient.
• Volume-targeted ventilation in advanced disease (e.g., ALS).
• Early initiation improves quality of life and survival (especially in Duchenne MD). [91]

---

11. Screening & Prevention

Screening Recommendations

Who Should Be Screened for OSA?

Screening should be targeted to high-risk populations. Universal screening is not currently recommended due to lack of cost-effectiveness data.

High-Risk Groups Requiring Screening:

1. Obesity (BMI greater than 30) or Neck Circumference greater than 43cm (M), greater than 40.5cm (F).
2. Resistant Hypertension (uncontrolled on ≥3 medications, including a diuretic).
3. Atrial Fibrillation (especially paroxysmal or recurrent post-ablation).
4. Heart Failure (HFrEF or HFpEF).
5. Stroke or TIA (50-70% have OSA).
6. Type 2 Diabetes (especially if obese).
7. Pre-operative assessment for bariatric surgery, upper airway surgery, or major surgery in obese patients.
8. Commercial drivers (HGV, bus, train) with snoring or sleepiness.
9. Pregnancy with chronic hypertension, gestational hypertension, or preeclampsia.
10. Down Syndrome (screen all).
11. Acromegaly or Hypothyroidism.

Screening Tools:

Prevention Strategies

Primary Prevention (Preventing OSA Development):

1. Weight Management: Maintain BMI less than 25 kg/m². Key intervention – obesity is the most modifiable risk factor.
2. Avoid Smoking: Smoking increases OSA risk 2.5-fold. [36]
3. Limit Alcohol: Especially before bed (relaxes pharyngeal muscles).
4. Sleep Position: Encourage lateral (side) sleeping vs. supine in at-risk individuals.
5. Treat Nasal Obstruction: Manage chronic rhinosinusitis, deviated septum, allergic rhinitis (improves nasal breathing and reduces mouth-breathing).

Secondary Prevention (Early Detection & Treatment to Prevent Complications):

1. Screen High-Risk Populations (see above).
2. Early CPAP Initiation: Prevents progression of cardiovascular disease, metabolic dysfunction, and cognitive decline.
3. BP Monitoring: OSA patients should have ambulatory BP monitoring (identify non-dipping pattern).
4. Diabetes Screening: HbA1c annually in OSA patients (especially if obese).

Tertiary Prevention (Preventing Complications in Diagnosed OSA):

1. CPAP Adherence Support: Telemedicine, troubleshooting, mask fitting clinics.
2. Cardiovascular Risk Modification: Statin, antiplatelet therapy (if indicated for CAD/stroke risk).
3. Driving Safety Counseling: DVLA notification, avoid driving if sleepy.

---

12. Driving Regulations (UK DVLA / US DMV)

Driving is a privilege, not a right. The law focuses on "Excessive Sleepiness", not just AHI.

The Rules (DVLA UK)

[!IMPORTANT] Key Legal advice: "You must inform the DVLA if you have OSA with sleepiness." Failure to do so can lead to a £1000 fine and insurance invalidation.

---

12. Driving Regulations (UK DVLA / US DMV)

Driving is a privilege, not a right. The law focuses on "Excessive Sleepiness", not just AHI.

The Rules (DVLA UK)

[!IMPORTANT] Key Legal advice: "You must inform the DVLA if you have OSA with sleepiness." Failure to do so can lead to a £1000 fine and insurance invalidation.

---

13. Evidence & Guidelines

Key Guidelines

1. NICE NG202 (2021) — Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s.
   • Rec: CPAP is recommended for moderate/severe symptomatic OSAHS.
   • Rec: MAD can be considered for mild symptomatic OSAHS.
2. American Academy of Sleep Medicine (AASM 2017) — Clinical Practice Guideline for Diagnostic Testing.
   • Rec: HSAT is appropriate for uncomplicated adult patients with increased risk.

Landmark Trials

The SAVE Trial (2016)

• Study: CPAP vs Usual Care in secondary prevention of CV events.
• Finding: CPAP improved QoL and mood, but functional outcomes did not show significant reduction in Stroke/MI rates in this cohort (possibly due to adherence issues ~3.3 hrs/night).
• Impact: Highlighted that "prescribing" CPAP isn't enough; adherence (> 4h) is key for CV benefit. Or maybe OSA is a marker, not just a cause.

The MERGE Trial (2019)

• Study: CPAP in mild OSA.
• Finding: Significant improvement in quality of life outcomes.
• Impact: Supports treating mild symptomatic disease.

The Pepperell Trial (2002)

• Study: CPAP vs Sham CPAP on Blood Pressure.
• Finding: CPAP reduced mean ambulatory BP by 2.5 mmHg (significant).
• Impact: Proves causal link between OSA and Hypertension.

---

14. Patient/Layperson Explanation

The "Soggy Straw" Analogy

Imagine trying to drink a thick milkshake through a soggy paper straw. When you suck hard, the straw walls collapse in, and nothing comes through. In Sleep Apnea, your throat is the straw. When you fall asleep, the muscles relax (get soggy). When you breathe in, the airway collapses.

Why do I snore?

Snoring is the sound of the air vibrating through the narrow, floppy tube. When it stops (Apnea), the tube has fully closed. The "Choke" is your brain waking you up to stiffen the tube and take a breath.

Why CPAP?

CPAP is like putting a rigid stent inside the straw. The air pressure acts like an invisible splint, holding the airway open so you can breathe and sleep deeply without interruption.

---

15. References

1. Peppard PE, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-21. PMID: 11122588
2. Marin JM, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365(9464):1046-53. PMID: 15781100
3. McEvoy RD, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea (SAVE Trial). N Engl J Med. 2016;375:919-931. PMID: 27571048
4. Wimms A, et al. Continuous positive airway pressure for mild obstructive sleep apnoea (The MERGE Trial). Lancet Respir Med. 2019. PMID: 31677977
5. Strollo PJ Jr, et al. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014;370:139-149. PMID: 24401051
6. Phillips CL, et al. Health outcomes of continuous positive airway pressure versus oral appliance treatment for obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med. 2013;187(8):879-87. PMID: 23413266
7. Epstein LJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263-76. PMID: 19960649
8. Young T, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328(17):1230-5. PMID: 8464434
9. Punjabi NM, et al. Sleep-disordered breathing and insulin resistance in middle-aged and older men. Am J Respir Crit Care Med. 2004;170(5):535-40. PMID: 15184206
10. Somers VK, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement. Circulation. 2008. PMID: 18725495
11. Gottlieb DJ, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010. PMID: 20625114
12. Redline S, et al. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med. 2010. PMID: 20339144
13. Yaggi HK, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005. PMID: 16282178
14. Barbé F, et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med. 2010. PMID: 20093641
15. Martinez-Garcia MA, et al. Sleep-disordered breathing in patients with difficult-to-control hypertension. Arch Intern Med. 2006. PMID: 16415412
16. Nieto FJ, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA. 2000. PMID: 10770144
17. Floras JS. Sleep apnea and cardiovascular risk. J Cardiol. 2014. PMID: 24332463
18. Chobanian AV, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003. PMID: 14656957
19. Mokhlesi B, et al. Obstructive sleep apnea during REM sleep and hypertension. the Wisconsin Sleep Cohort. Am J Respir Crit Care Med. 2014. PMID: 25089758
20. National Institute for Health and Care Excellence (NICE). Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s [NG202]. 2021.
21. Chung F, et al. High STOP-Bang score. Br J Anaesth. 2012. PMID: 22401627
22. Pepperell JCB, et al. Ambulatory blood pressure after... CPAP. Lancet. 2002;359(9302):204-10. PMID: 11812555
23. Benjafield AV, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687-698. PMID: 31300334
24. Lyons MM, et al. Global burden of sleep-disordered breathing and its implications. Respirology. 2020;25(7):690-702. PMID: 32436658
25. Peppard PE, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006-14. PMID: 23589584
26. Heinzer R, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med. 2015;3(4):310-8. PMID: 25682233
27. Kapur V, et al. Underdiagnosis of sleep apnea syndrome in U.S. communities. Sleep Breath. 2002;6(2):49-54. PMID: 12075479
28. Yaffe K, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. 2011;306(6):613-9. PMID: 21828324
29. Li KK, et al. Craniofacial characteristics of Asian and Caucasian patients with obstructive sleep apnea syndrome: an anthropometric study. Am J Orthod Dentofacial Orthop. 2000;118(6):714-20. PMID: 11113809
30. Peppard PE, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006-14. PMID: 23589584
31. Davies RJ, et al. Neck circumference and other clinical features in the diagnosis of the obstructive sleep apnoea syndrome. Thorax. 1992;47(2):101-5. PMID: 1549815
32. Marcus CL, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2012;130(3):e714-55. PMID: 22926176
33. Herrmann BL, et al. Impact of disease activity on sleep apnoea in patients with acromegaly. Eur J Endocrinol. 2004;151(4):459-65. PMID: 15476445
34. Young T, et al. Nasal obstruction as a risk factor for sleep-disordered breathing. J Allergy Clin Immunol. 1997;99(2):S757-62. PMID: 9042068
35. Scanlan MF, et al. Effect of moderate alcohol upon obstructive sleep apnoea. Eur Respir J. 2000;16(5):909-13. PMID: 11153591
36. Kashyap R, et al. Higher prevalence of smoking in patients diagnosed as having obstructive sleep apnea. Sleep Breath. 2001;5(4):167-72. PMID: 11868156
37. Walker JM, et al. The effect of opioids on sleep architecture. J Clin Sleep Med. 2007;3(1):33-6. PMID: 17557450
38. Oksenberg A, et al. Positional vs nonpositional obstructive sleep apnea patients. Chest. 1997;112(3):629-39. PMID: 9315794
39. Grunstein RR, et al. Sleep-disordered breathing in hypothyroidism. Am Rev Respir Dis. 1988;138(6):1535-9. PMID: 3202497
40. Punjabi NM, et al. Sleep-disordered breathing, glucose intolerance, and insulin resistance. Am J Epidemiol. 2004;160(6):521-30. PMID: 15353412
41. Vgontzas AN, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001;86(2):517-20. PMID: 11158002
42. Izci Balserak B, et al. Sleep-disordered breathing in pregnancy. Breathe (Sheff). 2015;11(4):268-77. PMID: 26929863
43. Johnson KG, et al. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J Clin Sleep Med. 2010;6(2):131-7. PMID: 20411688
44. Hanly PJ, et al. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med. 2001;344(2):102-7. PMID: 11150360
45. Redline S, et al. The genetics of sleep apnea. Sleep Med Rev. 1997;1(1):47-60. PMID: 15310523
46. Schwab RJ, et al. Upper airway imaging. Clin Chest Med. 1998;19(1):33-54. PMID: 9554216
47. Gold AR, et al. Inspiratory airflow dynamics during sleep in women with sleep apnea. J Appl Physiol. 2003;94(5):1746-52. PMID: 12533493
48. Somers VK, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96(4):1897-904. PMID: 7560081
49. Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia--revisited--the bad ugly and good: implications to the heart and brain. Sleep Med Rev. 2015;20:27-45. PMID: 25155182
50. Vgontzas AN, et al. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997;82(5):1313-6. PMID: 9141509
51. Ip MS, et al. Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med. 2004;169(3):348-53. PMID: 14551167
52. Carlson JT, et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest. 1993;103(6):1763-8. PMID: 8404098
53. von Känel R, et al. Effects of continuous positive airway pressure on fibrinogen in obstructive sleep apnea syndrome. Chest. 2006;129(3):581-7. PMID: 16537854
54. Kasai T, et al. Atrial natriuretic peptide in patients with obstructive sleep apnea. Chest. 2005;127(5):1675-9. PMID: 15888844
55. Suzuki M, et al. Circadian variation of blood pressure in patients with sleep apnea syndrome. Intern Med. 1996;35(8):632-6. PMID: 8894711
56. Hla KM, et al. Sleep apnea and hypertension. A population-based study. Ann Intern Med. 1994;120(5):382-8. PMID: 8304655
57. Stuck BA, et al. Diagnosis and treatment of snoring in adults--S2k Guideline of the German Society of Otorhinolaryngology, Head and Neck Surgery. Sleep Breath. 2015;19(1):135-48. PMID: 24817722
58. Lavie P, et al. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ. 2000;320(7233):479-82. PMID: 10678860
59. Logan AG, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19(12):2271-7. PMID: 11725173
60. Fava C, et al. Effect of CPAP on blood pressure in patients with OSA/hypopnea a systematic review and meta-analysis. Chest. 2014;145(4):762-71. PMID: 24077050
61. Gami AS, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004;110(4):364-7. PMID: 15249509
62. Naruse Y, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation. Int J Cardiol. 2013;164(2):201-6. PMID: 21839541
63. Fein AS, et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol. 2013;62(4):300-5. PMID: 23623910
64. Oldenburg O, et al. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. Eur J Heart Fail. 2007;9(3):251-7. PMID: 17027333
65. Gami AS, et al. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med. 2005;352(12):1206-14. PMID: 15788497
66. Gami AS, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49(5):565-71. PMID: 17276180
67. Pamidi S, et al. Obstructive sleep apnea in young lean men: impact on insulin sensitivity and secretion. Diabetes Care. 2012;35(11):2384-9. PMID: 22912423
68. Coughlin SR, et al. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J. 2004;25(9):735-41. PMID: 15120883
69. Li J, et al. Obstructive sleep apnea and the dyslipidemia: from epidemiology to mechanisms. Expert Rev Respir Med. 2014;8(3):301-15. PMID: 24650220
70. Musso G, et al. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev. 2013;14(5):417-31. PMID: 23387384
71. Beebe DW, et al. The neuropsychological effects of obstructive sleep apnea: a meta-analysis of norm-referenced and case-controlled data. Sleep. 2003;26(3):298-307. PMID: 12749549
72. Osorio RS, et al. Sleep-disordered breathing advances cognitive decline in the elderly. Neurology. 2015;84(19):1964-71. PMID: 25878183
73. Ancoli-Israel S, et al. Cognitive effects of treating obstructive sleep apnea in Alzheimer's disease: a randomized controlled study. J Am Geriatr Soc. 2008;56(11):2076-81. PMID: 18795985
74. Harris M, et al. Depression and sleep in patients with obstructive sleep apnea: an intervention study. Prim Care Companion J Clin Psychiatry. 2009;11(1):17-23. PMID: 19333404
75. Tregear S, et al. Obstructive sleep apnea and risk of motor vehicle crash: systematic review and meta-analysis. J Clin Sleep Med. 2009;5(6):573-81. PMID: 20465027
76. Bourjeily G, et al. Maternal and fetal outcomes in pregnancies with obstructive sleep apnea. Sleep Med. 2021;86:139-145. PMID: 34523292
77. Louis JM, et al. Maternal and neonatal morbidities associated with obstructive sleep apnea complicating pregnancy. Am J Obstet Gynecol. 2010;202(3):261.e1-5. PMID: 20005507
78. Bassan H, et al. Association of obstructive sleep apnea with adverse pregnancy-related outcomes in military hospitals. J Matern Fetal Neonatal Med. 2017;30(22):2631-2636. PMID: 28040612
79. Facco FL, et al. Obstructive sleep apnea in pregnancy is associated with adverse maternal outcomes: a national cohort. Sleep Med. 2017;38:50-57. PMID: 29031756
80. O'Brien LM, et al. Obstructive sleep apnea screening in pregnancy, perinatal outcomes, and impact of maternal obesity. Am J Perinatol. 2013;30(2):83-90. PMID: 21480159
81. Bourjeily G, et al. Obstructive Sleep Apnea in Pregnancy: A Comprehensive Review of Maternal and Fetal Implications. Obstet Gynecol Surv. 2024;79(6):379-391. PMID: 38804478
82. Guilleminault C, et al. A prospective study on the surgical outcomes of children with sleep-disordered breathing. Sleep. 2007;30(3):324-30. PMID: 17425228
83. Nagappa M, et al. Validation of the STOP-Bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis. PLoS One. 2015;10(12):e0143697. PMID: 26658438
84. Ahmed SB, et al. Chronic kidney disease and obstructive sleep apnea: a new association with clinical implications. Curr Opin Pulm Med. 2007;13(6):479-83. PMID: 17901753
85. Mojon DS, et al. Normal-tension glaucoma is associated with sleep apnea syndrome. Ophthalmologica. 2002;216(3):180-4. PMID: 12065854
86. Ing AJ, et al. Obstructive sleep apnea and gastroesophageal reflux. Am J Med. 2000;108 Suppl 4 a:120S-125S. PMID: 10718464
87. Teloken PE, et al. Defining association between sleep apnea syndrome and erectile dysfunction. Urology. 2006;67(5):1033-7. PMID: 16698365
88. McMillan A, et al. Continuous positive airway pressure in older people with obstructive sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial. Lancet Respir Med. 2014;2(10):804-12. PMID: 25172769
89. Ye L, et al. The different clinical faces of obstructive sleep apnoea: a systematic review. Sleep Med Rev. 2014;18(5):349-58. PMID: 24581371
90. Trois MS, et al. Obstructive sleep apnea in adults with Down syndrome. J Clin Sleep Med. 2009;5(4):317-23. PMID: 19968008
91. Eagle M, et al. Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord. 2007;17(6):470-5. PMID: 17490881
92. Chung F, et al. STOP-Bang questionnaire: a practical approach to screen for obstructive sleep apnea. Chest. 2016;149(3):631-8. PMID: 26378880

---

16. Examination Focus

Common Exam Questions

"Interpret this sleep study report. What is the AHI?" "Explain the DVLA rules for a Group 1 driver with OSA." "Demonstrate how to measure neck circumference."

Viva Points

Opening Statement: "Obstructive Sleep Apnea is a common disorder of upper airway collapse during sleep, characterized by apneas, hypoxemia, and sleep fragmentation. It is a major reversible risk factor for cardiovascular disease. Diagnosis is by Polysomnography (AHI > 5), and first-line management for symptomatic disease is CPAP."

"How does CPAP reduce blood pressure?"

• "By preventing apneas, CPAP abolishes the nocturnal sympathetic surges and catecholamine spikes. This reduces nocturnal BP and resets the baroreceptor sensitivity."

"What is the difference between Central and Obstructive Sleep Apnea?"

• "Obstructive: Respiratory effort is PRESENT (chest moves) but airflow is ABSENT (blocked).
• Central: Respiratory effort is ABSENT (brain doesn't signal) and airflow is ABSENT."

"What defines 'Success' in CPAP therapy?"

• "AHI less than 5 (Normalisation) AND Symptomatic improvement (ESS less than 10) AND Compliance (> 4 hours/night)."

Common Mistakes

• ❌ Diagnosing OSA solely on Epworth Score (it's a screening tool, not diagnostic).
• ❌ Ignoring the Nasal Airway (Deviated septum makes CPAP intolerable).
• ❌ Failing to advise the patient to inform the DVLA (Legal obligation).
• ❌ Prescribing sedatives/opiates to a snorer without ruling out OSA (Can precipitate respiratory arrest).

---

Last Reviewed: 2026-01-02 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.